---
title: "Varegacestat (AL102) in Desmoid tumors: Economic impact of diagnostic testing"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: Economic impact of diagnostic testing. Topics: Cost of centralized histological review in the French RRePS network, Molecular testing and unit costs of review in the French RRePS network, Concordance and 12-month management cost by initial and final diagnosis involving desmoid tumors, CTNNB1 and APC testing uptake at a United Kingdom specialist center, and 5 further topics. 9 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description/economic-impact-of-diagnostic-testing"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: Economic impact of diagnostic testing

<a id="heading-2.2.1.8.4"></a>

## 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

### Cost of centralized histological review in the French RRePS network

> “A decision tree was used to assess the expected costs of two strategies of disease management: one based on revised diagnoses after centralized histological review (option 1), the other on diagnoses without centralized review (option 2).”
> “The time horizon was 12 months and the perspective of the French National Health Insurance (NHI) was retained. Costs were expressed in Euros for 2013.”
> “A total of 2,425 patients were included. Three hundred forty-one patients (14%) had received discordant diagnoses.”
> “The probability of discordance was higher for a final diagnosis of desmoid tumors when compared to liposarcomas (odds ratio = 5.1; 95%CI [2.6–10.4]). The expected costs per patient for the base-case analysis (low- and high-case scenarios) amounted to €8,791 (€7,033 and €10,549, respectively) for option 1 and €8,904 (€7,057 and €10,750, respectively) for option 2.”
> “Centralized histological reviews are likely to provide cost-savings for the French NHI.”

Source: [Perrier et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5886412/)

<a id="topic-2.2.1.8.4-2"></a>

### Molecular testing and unit costs of review in the French RRePS network

> “Each center reviewed cases from the corresponding area using systematic molecular testing for every tumor that was suspected to have a specific genomic abnormality (e.g., KIT and PDGFRA mutations for GIST, CTNNB1 mutation for desmoid tumors, specific translocations for sarcomas with a recurrent translocation, and MDM2/CDK4 amplifications for atypical/well-differentiated and dedifferentiated liposarcomas).”
> “RRePS network organization (per patient)”
> “€103”
> “Histological review (per patient)”
> “€228”

Source: [Perrier et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5886412/)

<a id="topic-2.2.1.8.4-3"></a>

### Concordance and 12-month management cost by initial and final diagnosis involving desmoid tumors

| Initial diagnosis and final diagnosis | Mean cost of disease management, base case (2013 euros) | High scenario | Low scenario |
| --- | --- | --- | --- |
| Initial desmoid tumor, final desmoid tumor | “€1,219” | “€1,462” | “€975” |
| Initial desmoid tumor, final sarcoma | “€4,963” | “€5,955” | “€3,970” |
| Initial desmoid tumor, final benign tumor | “€640” | “€767” | “€512” |
| Initial sarcoma, final desmoid tumor | “€1,469” | “€1,762” | “€1,175” |
| Initial GIST, final desmoid tumor | “€839” | “€1,006” | “€671” |
| Initial benign tumor, final desmoid tumor | “€1,380” | “€1,655” | “€1,104” |

Source: [Perrier et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5886412/)

<a id="topic-2.2.1.8.4-4"></a>

### CTNNB1 and APC testing uptake at a United Kingdom specialist center

> “226 patients were identified and 67% (n = 152) were female. Median age at diagnosis was 37.5 (range 2-81) years.”
> “Colonoscopy was requested in 65 patients (28.8% of all cases) and was completed in forty-six (20.4%). Molecular testing of CTNNB1 testing was requested in 35 cases (15.5%). APC germline test was requested in 12 cases. Four patients in our cohort had an FAP-associated DF.”
> “CTNNB1 molecular testing should be performed in all cases of newly diagnosed DF. Negative CTNNB1 results, alongside clinical assessment, should prompt APC testing and/or colonoscopy.”

Source: [Cojocaru et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/33547536/)

<a id="topic-2.2.1.8.4-5"></a>

### CTNNB1 testing uptake, cost, and reimbursement at a United States academic center

> “A much smaller proportion of patients had documentation of CTNNB1 testing (n = 10, 6.7%), including seven with CTNNB1 mutation (4.7%) and three who were demonstrated to have the wild-type, nonmutated variant, which results in production of normal β-catenin (2%).”
> “Therefore, CTNNB1 testing is useful to diagnose or rule out DTs when APC mutations are not detected or morphologic features of DTs are inconclusive in the biopsy specimen (29). Notably, the proportion of patients with CTNNB1 testing was low in our participant cohort, potentially due to cost and reimbursement issues.”

Source: [Tan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13063223/)

<a id="topic-2.2.1.8.4-6"></a>

### Resource utilization before diagnosis among patients with potential misdiagnosis

> “A total of 43 patients (29.1%) potentially had a misdiagnosis prior to a final confirmed diagnosis of DT based on tissue histology (Table 4).”
> “In the first year prior to DT diagnosis, healthcare resource utilization was higher among patients with prior misdiagnoses, with a higher proportion of patients requiring outpatient visits (65.1% vs. 30.3%, P < 0.001), emergency room visits (14% vs. 2.6%, P = 0.03), and hospitalization (25.6% vs. 2.6%, P < 0.001; Table 4).”

Source: [Tan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13063223/)

<a id="topic-2.2.1.8.4-7"></a>

### Surgery before a definitive diagnosis in the Desmoid Tumor Research Foundation natural history study

> “A total of 162 participants (41%, 162/399) reported a prior misdiagnosis.”
> “Among 126 participants who reported a prior misdiagnosis and history of surgery for DT, 46% (58/126) reported having received surgery before a definitive DT diagnosis.”

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

<a id="topic-2.2.1.8.4-8"></a>

### Misdiagnosis during initial work-up and its consequences

> “misdiagnosis rates for DT may be as high as 30–40% during an initial work-up,”
> “which can result in additional treatments (eg, surgical excision) and delays for patients in receiving appropriate disease management.”

Source: [Kasper et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11166168/)

<a id="topic-2.2.1.8.4-9"></a>

### CTNNB1 genotyping and germline APC testing in children

> “Forty-four desmoids in pediatric patients were identified in the pathology files of 2 large referral centers (1995-2009).”
> “CTNNB1 mutations were observed in 29 of 44 (66%) desmoids, with 3 mutations identified: T41A (64%), S45F (29%), and S45P (7%). Germline APC mutations were present in 7 (16%) desmoid patients.”
> “Given the implications, genetic counseling is recommended for children diagnosed with desmoid tumors lacking CTNNB1 mutations because this population is enriched for FAP patients.”

Source: [Wang et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22372443/)

Additional sources: [Brueckl et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/15793634/)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
